SpringWorks Therapeutics Income Statement

Financials in millions TTD. Fiscal year is January - December.

Millions TTD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	3,780	3,386	2,564	2,149
Revenue Growth (YoY)	44.89%	32.07%	19.29%	-
Cost of Revenue	2,762	2,480	1,905	1,542
Gross Profit	1,018	906.41	659.15	607.74
Selling, General & Admin	690.81	690.81	435.48	418.72
Other Operating Expenses	85.83	-11.8	-0.4	-0.58
Operating Expenses	780.03	682.39	439.51	425.29
Operating Income	238.22	224.01	219.65	182.45
Interest Expense	-93.25	-83.86	-53.93	-40.45
Earnings From Equity Investments	0.79	0.02	0.05	2.18
Pretax Income	145.77	140.17	165.77	144.17
Income Tax Expense	78.68	76.32	25.94	24.78
Earnings From Continuing Operations	67.09	63.85	139.83	119.39
Minority Interest in Earnings	-12.36	-10.13	-11.06	-7.34
Net Income	54.73	53.73	128.77	112.06
Net Income to Common	54.73	53.73	128.77	112.06
Net Income Growth	-53.06%	-58.28%	14.91%	-
Shares Outstanding (Basic)	1,510	1,485	1,390	1,297
Shares Outstanding (Diluted)	1,510	1,485	1,390	1,297
Shares Change (YoY)	5.55%	6.83%	7.11%	-
EPS (Basic)	0.04	0.04	0.09	0.09
EPS (Diluted)	0.04	0.04	0.09	0.09
EPS Growth	-55.53%	-60.94%	7.28%	-
Free Cash Flow	143.78	40.84	82.94	-316.09
Free Cash Flow Per Share	0.10	0.03	0.06	-0.24
Dividend Per Share	0.026	0.026	0.025	0.022
Dividend Growth	5.00%	5.00%	16.67%	-
Gross Margin	26.94%	26.77%	25.71%	28.28%
Operating Margin	6.30%	6.62%	8.57%	8.49%
Profit Margin	1.45%	1.59%	5.02%	5.21%
Free Cash Flow Margin	3.80%	1.21%	3.23%	-14.71%
EBITDA	298.83	278.58	256.7	211.62
EBITDA Margin	7.90%	8.23%	10.01%	9.85%
D&A For EBITDA	60.6	54.57	37.06	29.17
EBIT	238.22	224.01	219.65	182.45
EBIT Margin	6.30%	6.62%	8.57%	8.49%
Effective Tax Rate	53.98%	54.45%	15.65%	17.19%
Advertising Expenses	-	48.8	34.22	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.